菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Biologics Commits to PSCI and Receives Award for Sustainable Supply Chain Leadership
Jan. 15, 2025
WuXi Biologics Commits to PSCI and Receives Award for Sustainable Supply Chain Leadership
  • Committed to PSCI principles to promote a responsible supply chain
  • Recognized for sustainable supply chain leadership
  • As a leading Green CRDMO, driven by innovation for a healthier future

     
Shanghai, January 15, 2025 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner, demonstrating its strong commitment to integrity, quality, reliability, and the advancement of responsible supply chain practices.

 

PSCI is the leading association for pharmaceutical and healthcare companies with a common vision of excellence in safety, environmental, and social outcomes across the global healthcare value chain. WuXi Biologics fully upholds PSCI principles for responsible supply chain practices in the areas of Ethics, Human Rights and Labor, Health and Safety, Environment, and Management Systems. The company embeds PSCI principles into its own supply chain management system, actively engaging and collaborating with global suppliers to drive best practices and generate positive impacts.

 

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “An inclusive, responsible, and resilient supply chain is key to our long-term business success, and we are pleased to join PSCI in advocating for responsible practices throughout the value chain. We will continuously deliver our own ESG excellence and enable our partners worldwide to fulfill their ESG commitments.”

 

WuXi Biologics was recognized by the 2024 Hong Kong ESG Reporting Awards with a Sustainable Supply Chain Leadership Award for its outstanding performance. The company strives to conduct business with partners who share the same commitment to high ethical and sustainability standards. To create a more transparent, ethical, and responsible supply chain, WuXi Biologics formulates sustainable supply chain policies, sets tangible targets, develops refined roadmaps, performs regular PSCI audits, provides training courses, and explores capacity-building programs.

 

In 2024, WuXi Biologics was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions. The company was granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional ESG Top-Rated Company by Sustainalytics; named to the CDP Water Security “A list” and awarded an “A-” CDP Climate Change score; selected as a Constituent of FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and non-COVID dormant CMO projects).

 

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

 

Contacts

 

Media

PR@wuxibiologics.com

 

ESG

esg@wuxibiologics.com